UY25711A1 - ADMINISTRATION OF DRY POWDER ACTIVE AGENT - Google Patents
ADMINISTRATION OF DRY POWDER ACTIVE AGENTInfo
- Publication number
- UY25711A1 UY25711A1 UY25711A UY25711A UY25711A1 UY 25711 A1 UY25711 A1 UY 25711A1 UY 25711 A UY25711 A UY 25711A UY 25711 A UY25711 A UY 25711A UY 25711 A1 UY25711 A1 UY 25711A1
- Authority
- UY
- Uruguay
- Prior art keywords
- particles
- active agent
- growth inhibitor
- administration
- alveoli
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Abstract
Partículas para la administración de un agente activo a los alvéolos de un paciente humano, partículas que contienen el agente activo y un inhibidor del crecimiento higroscópico que está incorporado al interior de las partículas y éstas exhiben una caída de la dosis emitida, en condiciones pulmonares simuladas, de no más de aproximadamente 25%. Las particulas en la cuales el inhibidor del crecimiento higrocópico es seleccionado entre el grupo que consiste en fosfolipidos de cadena doble, ciclodextrinas hidroxietilalmidón, dextrano, dextranómero, maltodextrano, hidroxipropilcelulosa, hidroxipropilmetilcelulosa, éter hidroxietilico de etilcelulosa. Particulas para la administración de un agente activo a los alvéolos de un paciente humano, particulas que contienen el agente activo y un inhibidor del crecimiento higroscopico incorporado al interior de las particulas que contienen el agente activo y un inhibidor del crecimiento higroscópico incorporado al interior de las particulas, donde dichas particulas mantienen una distribución de tamaño de particulas del aerosol inferior a 3 micrones de MMAD al ser administradas a los alvéolos. Un método para aumentar la cantidad de un agente activo inhalado deposiado en la profundidad del pulmón, que consiste en: incorporar a dichas particulas de polvo seco con contenido de agente activo para la inhalación, un agente inhibidor del crecimiento higrocópico de manera que, al ser aerosolizadas e inhaladas las particulas, por lo menos el 20% de la dosis nominal se deposite en la profundidad del pulmón.Particles for the administration of an active agent to the alveoli of a human patient, particles that contain the active agent and a hygroscopic growth inhibitor that is incorporated into the particles and these show a drop in the emitted dose, under simulated pulmonary conditions , of no more than about 25%. The particles in which the hygrocopic growth inhibitor is selected from the group consisting of double chain phospholipids, hydroxyethyl starch cyclodextrins, dextran, dextranomer, maltodextran, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethyl ether of ethylcellulose. Particles for the administration of an active agent to the alveoli of a human patient, particles containing the active agent and a hygroscopic growth inhibitor incorporated within the particles containing the active agent and a hygroscopic growth inhibitor incorporated within the particles, where said particles maintain an aerosol particle size distribution of less than 3 microns of MMAD when administered to the alveoli. A method to increase the amount of an inhaled active agent deposited deep within the lung, which consists of: incorporating into said dry powder particles with active agent content for inhalation, a hygrocopic growth inhibitor agent so that, by being aerosolized and inhaled the particles, at least 20% of the nominal dose is deposited in the depth of the lung.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10016398P | 1998-09-14 | 1998-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25711A1 true UY25711A1 (en) | 1999-11-17 |
Family
ID=22278404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25711A UY25711A1 (en) | 1998-09-14 | 1999-09-14 | ADMINISTRATION OF DRY POWDER ACTIVE AGENT |
Country Status (44)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1198593C (en) | 1999-06-09 | 2005-04-27 | 罗伯特·E·希弗斯 | Supercritical fluid-assisted nebulization and bubble drying |
| US6475468B2 (en) * | 2001-02-15 | 2002-11-05 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
| CA2446904A1 (en) * | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| EG24184A (en) * | 2001-06-15 | 2008-10-08 | Otsuka Pharma Co Ltd | Dry powder inhalation system for transpulmonary |
| US7759506B2 (en) | 2002-02-25 | 2010-07-20 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
| BR0307935A (en) | 2002-02-25 | 2005-03-29 | Diffusion Pharmaceuticals Llc | Bipolar Trans Carotenoid Salts And Their Uses |
| JP2006513139A (en) * | 2002-07-03 | 2006-04-20 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | Central airway administration for systemic delivery of therapeutic agents |
| ES2280835T3 (en) * | 2002-12-19 | 2007-09-16 | Pharmacia Corporation | NON-HYGROSCOPIC FORMULATION THAT INCLUDES A HYGROSCOPIC PHARMACO. |
| DE10338403A1 (en) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder formulation containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1 H) -oxoquinazolin-3-yl] -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyrindinyl) piperazine, process for its preparation and its use as inhalant |
| GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| CA2562585A1 (en) * | 2004-04-23 | 2005-11-10 | Cydex, Inc. | Dpi formulation containing sulfoalkyl ether cyclodextrin |
| CA2598882C (en) * | 2005-02-24 | 2020-02-25 | Diffusion Pharmaceuticals Llc | Trans carotenoids, their synthesis, formulation and uses |
| AU2006221364A1 (en) * | 2005-03-09 | 2006-09-14 | Ono Pharmaceutical Co., Ltd. | Particle and preparation containing the particle |
| SI2335707T1 (en) | 2005-10-26 | 2015-09-30 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| US20100269819A1 (en) * | 2006-08-14 | 2010-10-28 | Sievers Robert E | Human Powered Dry Powder Inhaler and Dry Powder Inhaler Compositions |
| WO2008050847A1 (en) * | 2006-10-25 | 2008-05-02 | Dainippon Sumitomo Pharma Co., Ltd. | Granular preparation prevented from caking |
| EP1925295A1 (en) * | 2006-11-22 | 2008-05-28 | Boehringer Ingelheim Pharma GmbH & Co. KG | Stable powder formulation containing a new antichinolinergic agent |
| JP2010524855A (en) | 2007-04-13 | 2010-07-22 | ディフュージョン・ファーマシューティカルズ・エルエルシー | Use of bipolar trans carotenoids as and in the pretreatment of peripheral vascular disease |
| CN101878040A (en) | 2007-10-31 | 2010-11-03 | 扩散药品有限公司 | A new class of therapeutics that enhance small molecule diffusion |
| ES2661215T3 (en) | 2009-05-20 | 2018-03-28 | Aeras | Viral compositions; immunogens; spray dried; stable |
| AU2010263245A1 (en) | 2009-06-22 | 2012-01-19 | Diffusion Pharmaceuticals Llc | Diffusion enhancing compounds and their use alone or with thrombolytics |
| KR101891357B1 (en) | 2010-06-02 | 2018-08-24 | 디퓨젼 파마슈티컬즈 엘엘씨 | Oral formulations of bipolar trans carotenoids |
| SG10201607288VA (en) | 2012-05-03 | 2016-10-28 | Janssen Sciences Ireland Uc | Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections |
| BR112015010601B1 (en) * | 2012-11-09 | 2022-07-19 | Civitas Therapeutics, Inc. | PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOSITION |
| WO2015042352A1 (en) * | 2013-09-20 | 2015-03-26 | Virginia Commonwealth University | Delivery of particles using hygroscopic excipients |
| DK3212212T3 (en) | 2014-10-31 | 2020-12-21 | Univ Monash | POWDER FORMULATION |
| KR20230014850A (en) | 2016-03-24 | 2023-01-30 | 디퓨젼 파마슈티컬즈 엘엘씨 | Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3155573A (en) * | 1958-05-06 | 1964-11-03 | Benger Lab Ltd | Inhalant composition and method of making same |
| ES2177544T3 (en) * | 1992-06-12 | 2002-12-16 | Teijin Ltd | ULTRAFININE POWDER TO INHALATE AND METHOD FOR PREPARATION. |
| US6524557B1 (en) * | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| DE69732306T2 (en) * | 1997-01-16 | 2006-01-12 | Massachusetts Institute Of Technology, Cambridge | PREPARATION OF PARTICLE MEDICINES FOR INHALATION |
| US6086376A (en) * | 1998-01-30 | 2000-07-11 | Rtp Pharma Inc. | Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant |
-
1999
- 1999-09-09 MA MA25762A patent/MA25590A1/en unknown
- 1999-09-13 MY MYPI99003947A patent/MY129282A/en unknown
- 1999-09-13 SK SK344-2001A patent/SK3442001A3/en unknown
- 1999-09-13 HU HU0103837A patent/HUP0103837A3/en unknown
- 1999-09-13 EE EEP200100151A patent/EE200100151A/en unknown
- 1999-09-13 IL IL14156299A patent/IL141562A0/en not_active IP Right Cessation
- 1999-09-13 EA EA200100300A patent/EA003476B1/en active IP Right Revival
- 1999-09-13 KR KR1020017003208A patent/KR20010075063A/en not_active Application Discontinuation
- 1999-09-13 CN CN99810871A patent/CN1317977A/en active Pending
- 1999-09-13 ID IDW20010582A patent/ID28845A/en unknown
- 1999-09-13 ZA ZA200101995A patent/ZA200101995B/en unknown
- 1999-09-13 PL PL99346768A patent/PL195574B1/en not_active IP Right Cessation
- 1999-09-13 UA UA2001031707A patent/UA76085C2/en unknown
- 1999-09-13 GE GEAP19995857A patent/GEP20043257B/en unknown
- 1999-09-13 PE PE1999000925A patent/PE20001061A1/en not_active Application Discontinuation
- 1999-09-13 CZ CZ2001829A patent/CZ2001829A3/en unknown
- 1999-09-13 EP EP99969035A patent/EP1117442A1/en not_active Withdrawn
- 1999-09-13 AU AU60397/99A patent/AU753014B2/en not_active Ceased
- 1999-09-13 AP APAP/P/2001/002093A patent/AP1374A/en active
- 1999-09-13 HN HN1999000159A patent/HN1999000159A/en unknown
- 1999-09-13 CA CA002343920A patent/CA2343920A1/en not_active Abandoned
- 1999-09-13 JP JP2000569846A patent/JP2002524535A/en not_active Withdrawn
- 1999-09-13 OA OA1200100063A patent/OA11781A/en unknown
- 1999-09-13 TR TR2001/01182T patent/TR200101182T2/en unknown
- 1999-09-13 TW TW088115876A patent/TWI226248B/en not_active IP Right Cessation
- 1999-09-13 WO PCT/US1999/021109 patent/WO2000015262A1/en not_active Application Discontinuation
- 1999-09-13 DZ DZ990192A patent/DZ2892A1/en active
- 1999-09-13 AR ARP990104587A patent/AR022090A1/en unknown
- 1999-09-13 BR BR9913722-4A patent/BR9913722A/en not_active IP Right Cessation
- 1999-09-13 NZ NZ510168A patent/NZ510168A/en unknown
- 1999-09-13 YU YU24201A patent/YU24201A/en unknown
- 1999-09-14 GT GT199900156A patent/GT199900156A/en unknown
- 1999-09-14 UY UY25711A patent/UY25711A1/en not_active Application Discontinuation
- 1999-09-14 CO CO99058265A patent/CO5130023A1/en unknown
- 1999-09-14 TN TNTNSN99173A patent/TNSN99173A1/en unknown
- 1999-09-14 PA PA19998481901A patent/PA8481901A1/en unknown
- 1999-10-31 SA SA99200718A patent/SA99200718B1/en unknown
-
2001
- 2001-02-21 IL IL141562A patent/IL141562A/en unknown
- 2001-03-05 IS IS5878A patent/IS5878A/en unknown
- 2001-03-13 NO NO20011251A patent/NO20011251L/en not_active Application Discontinuation
- 2001-03-14 LT LT2001021A patent/LT4897B/en not_active IP Right Cessation
- 2001-03-14 HR HR20010189A patent/HRP20010189A2/en not_active Application Discontinuation
- 2001-03-14 LV LV010041A patent/LV12658B/en unknown
- 2001-04-10 BG BG105430A patent/BG105430A/en unknown
-
2002
- 2002-03-06 HK HK02101738.3A patent/HK1042231A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25711A1 (en) | ADMINISTRATION OF DRY POWDER ACTIVE AGENT | |
| AU710821B2 (en) | Fluticasone propionate formulations | |
| US8858917B2 (en) | Methods for limiting spread of pulmonary infections | |
| Conley et al. | Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice | |
| US20070292519A1 (en) | Method of producing a nicotine medicament and a medicament made by the method | |
| CZ299348B6 (en) | Aerosol formulation | |
| JP2009529561A (en) | Stable lozenge composition providing rapid release of nicotine | |
| TR200502522T2 (en) | Pharmaceutical formulation containing an insoluble active ingredient | |
| PT756868E (en) | COMPOSITIONS IN AEROSSOIS | |
| AR018891A1 (en) | PRESSURIZED INHALERS OF DOSAGE MEASUREMENT AND PHARMACEUTICAL FORMULATIONS IN AEROSOL | |
| Thomson et al. | No demonstrable effect of S-carboxymethylcysteine on clearance of secretions from the human lung. | |
| US20120042886A1 (en) | Method of producing a nicotine medicament and a medicament made by the method | |
| Moosavi et al. | Early radiation dose-response in lung: an ultrastructural study | |
| US3667478A (en) | Filter cigarette incorporating vitamin a | |
| CA3019748C (en) | Ophthalmic composition comprising pvp-i | |
| US9427443B2 (en) | Anaesthetic composition | |
| RU2701514C2 (en) | Antiviral pharmaceutical composition | |
| Niven et al. | Solute absorption from the airways of the isolated rat lung. II. Effect of surfactants on absorption of fluorescein | |
| JPH02504030A (en) | Tablets that clean teeth and add fluoride | |
| FI962056A (en) | New pharmaceutical composition for the manufacture of stable powder containing as active ingredient a combination of acetylsalicylic acid and methoclopramide | |
| US20050220720A1 (en) | Formulations limiting spread of pulmonary infections | |
| KR20140001877A (en) | Method for treating cystic fibrosis with inhaled denufosol | |
| JP6721968B2 (en) | Bubble gingival retraction prevention and improvement agent | |
| Tarbell et al. | The effect of N-acetylcysteine inhalation on the tolerance to thoracic radiation in mice | |
| FI84697C (en) | A PROCEDURE FOR THE FRAMSTATION OF A PHARMACOLOGICAL COMPOSITION WITH DERIVATIVES OF PEROXIDE DOSPHOSPHORUS. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RDES | Application refused |
Effective date: 20081203 |